---
_schema: default
id: 166312
date: 2025-01-30
title: How does monoclonal antibody therapy work in treating lymphoma?
article_title: How does monoclonal antibody therapy work in treating lymphoma?
date_format: MMM DD, YYYY
post_on_text: Posted on
seo:
  title: QuickTakes | Health studies
  page_description: >-
    Monoclonal antibody therapy is a targeted treatment that enhances the immune system's ability to recognize and destroy lymphoma cells through mechanisms like antigen targeting, immune system activation, and blocking growth signals.
  page_keywords: >-
    monoclonal antibody therapy, lymphoma treatment, cancer therapy, immune system, CD20 antigen, rituximab, Non-Hodgkin's lymphoma, apoptosis, ADCC, complement activation, growth signals, Hodgkin's lymphoma, brentuximab vedotin, side effects, targeted therapy
author: QuickTakes
question: >-
    How does monoclonal antibody therapy work in treating lymphoma?
answer: >-
    Monoclonal antibody therapy is a targeted treatment approach that utilizes laboratory-made antibodies designed to bind to specific antigens present on cancer cells, including those found in lymphoma. This therapy enhances the immune system's ability to recognize and destroy cancer cells more effectively.\n\n### Mechanism of Action\n1. **Targeting Antigens**: Monoclonal antibodies are engineered to attach to unique proteins (antigens) on the surface of cancer cells. For example, in certain types of lymphoma, such as Non-Hodgkin's lymphoma, the CD20 antigen is commonly targeted by monoclonal antibodies like rituximab.\n\n2. **Immune System Activation**: Once the monoclonal antibody binds to the cancer cell, it can trigger several immune responses:\n   - **Direct Cell Death**: The binding can induce apoptosis (programmed cell death) in the cancer cells.\n   - **Antibody-Dependent Cellular Cytotoxicity (ADCC)**: The immune system's natural killer (NK) cells can recognize the antibody-coated cancer cells and destroy them.\n   - **Complement Activation**: The binding of the antibody can activate the complement system, leading to the lysis of the cancer cell.\n\n3. **Blocking Growth Signals**: Some monoclonal antibodies can inhibit growth factor receptors on cancer cells, preventing them from receiving signals that promote growth and survival.\n\n### Applications in Lymphoma Treatment\nMonoclonal antibody therapy is used in both Hodgkin's lymphoma and Non-Hodgkin's lymphoma. It can be administered alone or in combination with other treatments such as chemotherapy and radiation therapy. The use of monoclonal antibodies has been shown to improve treatment outcomes, particularly in cases where traditional therapies may be less effective.\n\n### Clinical Considerations\n- **Types of Monoclonal Antibodies**: Commonly used monoclonal antibodies in lymphoma treatment include rituximab (for CD20-positive B-cell lymphomas) and brentuximab vedotin (for CD30-positive lymphomas).\n- **Side Effects**: While generally well-tolerated, monoclonal antibody therapy can have side effects, including infusion reactions, increased risk of infections, and potential for tumor lysis syndrome.\n\nIn summary, monoclonal antibody therapy represents a significant advancement in the treatment of lymphoma, providing a targeted approach that enhances the immune response against cancer cells while minimizing damage to normal tissues. This therapy is part of a broader treatment strategy that may include chemotherapy and radiation, tailored to the specific type and stage of lymphoma.
subject: Health studies
file_name: how-does-monoclonal-antibody-therapy-work-in-treating-lymphoma.md
url: /learn/health-studies/questions/how-does-monoclonal-antibody-therapy-work-in-treating-lymphoma
---

&nbsp;